BCG vaccine
- Generic Name
- BCG vaccine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 8VJE55B0VG
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Associated Conditions
- Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer, Tuberculosis (TB), Urothelial Carcinoma Recurrent, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 40
- Registration Number
- NCT04134000
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 517
- Registration Number
- NCT03799835
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷Groupe Hospitalier Paris Saint Joseph, Paris, France
🇫🇷Hôpital privé de la Louvière, Lille, France
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1397
- Registration Number
- NCT03711032
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital ( Site 0409), Tokyo, Japan
🇺🇸Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083), Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix ( Site 1094), Phoenix, Arizona, United States
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 185
- Registration Number
- NCT02444611
- Locations
- 🇦🇺
Mercy Hospital for Women, Heidelberg, Victoria, Australia
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT01878188
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
🇮🇱Bnai Zion MC, Haifa, Israel
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Target Recruit Count
- 120
- Registration Number
- NCT01697306
- Locations
- 🇮🇹
A.O.U. San Giovanni Battista Molinette, Torino, TO, Italy
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- University Of Perugia
- Target Recruit Count
- 64
- Registration Number
- NCT00696579
- Locations
- 🇮🇹
1. Department of Medical-Surgical Specialties and Public Health, Section of Urology and Andrology, University of Perugia - Italy, Perugia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.